Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers  

作　　者：Zhe-Han Bao Can Hu Yan-Qiang Zhang Peng-Cheng Yu Yi Wang Zhi-Yuan Xu Huan-Ying Fu Xiang-Dong Cheng 

机构地区：[1]Department of Interventional Radiology,Zhejiang Cancer Hospital,Hangzhou 310004,Zhejiang Province,China [2]Department of Gastric Surgery,Zhejiang Cancer Hospital,Hangzhou 310022,Zhejiang Province,China [3]Department of Colonic Surgery,Jinhua Central Hospital,Jinhua 321000,Zhejiang Province,China [4]Department of Breast Surgery,Lin’an People’s Hospital,Hangzhou 311300,Zhejiang Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2024年第4期1281-1295,共15页世界胃肠肿瘤学杂志（英文版）（电子版）

基　　金：Supported by Medical Science and Technology Project of Zhejiang Province(2022KY085).

摘　　要：BACKGROUND Gastric cancer(GC)is the fifth most common and the fourth most lethal malignant tumour in the world.Most patients are already in the advanced stage when they are diagnosed,which also leads to poor overall survival.The effect of posto-perative adjuvant chemotherapy for advanced GC is unsatisfactory with a high rate of distant metastasis and local recurrence.AIM To investigate the safety and efficacy of a programmed cell death 1(PD-1)inhibitor combined with oxaliplatin and S-1(SOX)in the treatment of Borrmann large type III and IV GCs.METHODS A retrospective analysis(IRB-2022-371)was performed on 89 patients with Borrmann large type III and IV GCs who received neoadjuvant therapy(NAT)from January 2020 to December 2021.According to the different neoadjuvant treatment regimens,the patients were divided into the SOX group(61 patients)and the PD-1+SOX(P-SOX)group(28 patients).RESULTS The pathological response(tumor regression grade 0/1)in the P-SOX group was significantly higher than that in the SOX group(42.86%vs 18.03%,P=0.013).The incidence of ypN0 in the P-SOX group was higher than that in the SOX group(39.29%vs 19.67%,P=0.05).The use of PD-1 inhibitors was an independent factor affecting tumor regression grade.Meanwhile,the use of PD-1 did not increase postoperative complications or the adverse effects of NAT.CONCLUSION A PD-1 inhibitor combined with SOX could significantly improve the rate of tumour regression during NAT for patients with Borrmann large type III and IV GCs.

关 键 词：Neoadjuvant therapy IMMUNOTHERAPY Gastric cancer Borrmann type Tumor regression grade 

分 类 号：R735.2[医药卫生—肿瘤]